<?xml version="1.0" encoding="UTF-8"?>
<p id="p0230">In addition to COVID-19 vaccine clinical trials in China, there are many SARS-CoV-2 vaccine clinical trials underway worldwide [
 <xref rid="bib153" ref-type="bibr">153</xref>], such as a mRNA vaccine, mRNA-1273, produced by Moderna, Inc. in US (NCT04283461); a DNA vaccine, INO-4800 by Inovio, Inc. in US (NCT04336410); Bifidobacterium probiotic carrying S protein gene by Symvivo in Canada (NCT04334980); adenovirus vaccine vector carrying S protein in UK (NCT04324606), etc. Whereas SARS-CoV-2 only started emerging in the human population, S protein, a major direct receptor interaction protein, and other viral proteins may continue modifying themselves to better adapt to humans [
 <xref rid="bib154" ref-type="bibr">154</xref>]. Gene modification will bring more challenges into vaccine designing and development, especially the mutation in S protein which has been picked up by most of the vaccines candidates mentioned above.
</p>
